ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study

Feng, Yi; Wang, Runchen; Li, Caichen; Cai, Xiuyu; Huo, Zhenyu; Liu, Ziyu; Ge, Fan; Huang, Chuiguo; Lu, Yi; Zhong, Ran; Li, Jianfu; Cheng, Bo; Liang, Hengrui; Xiong, Shan; Mao, Xingyu; Chen, Yilin; Lan, Ruying; Wen, Yaokai; Peng, Haoxin; Jiang, Yu; Su, Zixuan; Wu, Xiangrong; He, Jianxing; Liang, Wenhua广州医学院; 南方医科大学; 上海应用技术学院; 中山大学; 1
Translational Lung Cancer Research2022-7DOI: 10.21037/tlcr-22-34
8被引6阅读
引用收藏
分享

摘要

Background: Previous studies have shown that metabolites play important roles in phenotypic regulation, but the causal link between metabolites and tumors has not been examined adequately. Herein, we investigate the causality between metabolites and various cancers through a Mendelian randomization (MR) study. Methods: We carried out a two-sample MR analysis based on genetic instrumental variables as proxies for 486 selected human serum metabolites to evaluate the causal effects of genetically determined metabotypes (GDMs) on cancers. Summary data from various cancer types obtained from large consortia. Inverse variance weighted (IVW), MR-Egger and weighted-median methods were implemented to infer the causal effects, moreover, we particularly explored the presentence of horizontal pleiotropy through MR-Egger regression and MR-PRESSO Global test. Metabolic pathways analysis and subgroup analyses were further explored using available data. Statistical analyses were all performed in R. Results: In MR analysis, 202 significant causative relationship features were identified. 7-alpha-hydroxy-3-oxo-4-cholestenoate (ORIVW =1.45; 95% CI: 1.06-1.97; PIVW=0.018), gamma-glutamylisoleucine (ORIVW =1.40; 95% CI: 1.16-1.69; PIVW=0.0004), 1-oleoylglycerophosphocholine (ORIVW =1.22; 95% CI: 1.1-1.35; PIVW=0.0001), gamma-glutamylleucine (ORIVW=4.74; 95% CI: 1.18-18.93; PIVW=0.027) were the most dangerous metabolites for lung cancer, ovarian cancer, breast cancer, and glioma, respectively; while pseudouridine (ORIVW =0.50; 95% CI: 0.30-0.83; PIVW=0.007), 2-methylbutyroylcarnitine (ORIVW =0.77; 95% CI: 0.68-0.86; PIVW=2.9x10-6), 2-methylbutyroylcarnitine (ORIVW =0.77; 95% CI: 0.70-0.85; PIVW=3.4x10-7), glycylvaline (ORIVW=0.13; 95% CI: 0.02-0.75; PIVW=0.021) were associated with lower risk of lung cancer, ovarian cancer, breast cancer, and glioma, respectively. Interestingly, 2-methylbutyroylcarnitine was also associated with decreased risk of lung cancer (ORIVW =0.59; 0.50-0.70; PIVW =1.98x10-9) expect ovarian cancer and breast cancer. In subgroup analysis, 2-methylbutyroylcarnitine was associated with decreased risk of ER (estrogen receptor) positive breast cancer (ORIVW =0.72; 0.64-0.80; PIVW=3.55x10-9), lung adenocarcinoma (LAC) (ORIVW =0.60; 0.48-0.70; PIVW =1.14x10-5). Metabolic pathways analysis identified 4 significant pathways. Conclusions: Our study integrated metabolomics and genomics to explore the risk factors involved in the development of cancers. It is worth exploring whether metabolites with causality can be used as biomarkers to distinguish patients at high risk of cancer in clinical practice. More detailed studies are needed to clarify the mechanistic pathways.

学科与关键词

关键词
Serum metabolitecancerMendelian randomization (MR)2-methylbutyroylcarnitine
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Translational Lung Cancer Research
发表日期
2022-07
卷期
第 11 卷, 第 7 期
页码
1302-1314
DOI
10.21037/tlcr-22-34
期刊等级
2区
成果收录
SCIE
资助标注
China National Science Foundation [82022048, 81871893]; Key Project of Guangzhou Scientific Research Project [201804020030]

作者

  • F

    Feng, Yi (第一作者)

    1 · guangzhou med univ

  • W

    Wang, Runchen

    1 · guangzhou med univ

查看全部 24 位作者收起作者
  • L

    Li, Caichen

    1 · guangzhou med univ

  • C

    Cai, Xiuyu

  • H

    Huo, Zhenyu

    1 · guangzhou med univ

  • L

    Liu, Ziyu

    1 · guangzhou med univ

  • G

    Ge, Fan

    1 · guangzhou med univ

  • H

    Huang, Chuiguo

  • L

    Lu, Yi

    1 · guangzhou med univ

  • Z

    Zhong, Ran

    1 · guangzhou med univ

  • L

    Li, Jianfu

    1 · guangzhou med univ

  • C

    Cheng, Bo

    1 · guangzhou med univ

  • L

    Liang, Hengrui

    1 · guangzhou med univ

  • X

    Xiong, Shan

    1 · guangzhou med univ

  • M

    Mao, Xingyu

  • C

    Chen, Yilin

  • L

    Lan, Ruying

    1 · guangzhou med univ

  • W

    Wen, Yaokai

    1 · guangzhou med univ

  • P

    Peng, Haoxin

    1 · guangzhou med univ

  • J

    Jiang, Yu

    1 · guangzhou med univ

  • S

    Su, Zixuan

    1 · guangzhou med univ

  • W

    Wu, Xiangrong

    1 · guangzhou med univ

  • H

    He, Jianxing

    1 · guangzhou med univ

  • L

    Liang, Wenhua

    1 · guangzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417